Telomir Pharmaceuticals, Inc. · NASDAQ:TELO
Telomir Pharmaceuticals — Investor Presentation (January 2025)
28 slides from Telomir Pharmaceuticals's investor presentation, January 2025
Slide 1: January 2025 Investor Presentation
January 2025 Investor Presentation Nasdaq: TELO
Slide 2: Disclaimers and Cautionary Note on Forward Looking Statements
DISCLAIMERS AND CAUTIONARY NOTE ON FORWARD LOOKING STATEMENTS This presentation, statements of Telomir Pharmaceuticals’ management or advisors related thereto, and the statements contained in the news story linked in this release contain “forward-looking statements,” which are statements other than
Slide 3: Corporate Overview
CORPORATE OVERVIEW Telomir Pharmaceuticals Inc. (Nasdaq: TELO) is a pre-clinical-stage pharmaceutical company leading the development of age-reversal science by focusing on addressing the root causes of age-related conditions, rather than just managing the Symptoms. Telomir-1 is a novel small molecu
Slide 4: Telomir Management
TELOMIR MANAGEMENT Erez Aminov | Chairman & CEO Itzchak Angel, PhD | Chief Scientific Advisor ▪ A biotechnology leader driving innovation in drug ▪ Over 40 years of experience in guiding medical, development and strategic growth. pharmaceutical, drug, and business development in both large and emerg
Slide 5: Telomir Advisors
TELOMIR ADVISORS Francis E. O’Donnell, JR., M.D. | Special Advisor Mark Oken | Special Advisor ▪ Dr. O’Donnell, leads clinical strategy and ▪ Mr. Oken, chairman of Falfurrias Capital, co- evaluates potential products for unmet founded the firm and manages its portfolio. medical needs ▪ Formerly Bank
Slide 6: Therapeutic Research Approaches for Telomir-1
THERAPEUTIC RESEARCH Investigating Telomir-1’s Explore the interactions APPROACHES T E L O M I R P H A R M A . C O M effects on copper and iron between iron, copper and regulation at the cellular zinc on variable cellular FOR TELOMIR-1 level and in preclinical functions focusing on models. Telomere
Slide 7: Impact of Iron Overload
IMPACT OF IRON OVERLOAD Cellular ▪ Oxidative stress ▪ Mitochondrial dysfunction ▪ DNA dysfunction IRON OVERLOAD ▪ Ferroptosis ▪ Cellular senescence T E L O M I R P H A R M A . C O M Functional ▪ Accelerated aging ▪ Senescence Pathology ▪ Telomer shortening ▪ Progeria ▪ Insulin resistance ▪ Metabolic
Slide 8: Impact of Iron and Copper Overload
Impact of Iron and Copper Overload IRON OVERLOAD C O PP E R O VE R LO AD T E L O M I R P H A R M A . C O M Accelerated Aging Metabolic Syndrome Alzheimer’s Wilson’s Disease Disease Fredrick’s Ataxia Menkes Disease Hemochromatosis AMD AMD Investor Presentation | Nasdaq: TELO 08
Slide 9: Therapeutic Focus Areas
THERAPEUTIC FOCUS AREAS Key ongoing initiatives include: Progeria Research Type 2 Diabetes Studies Macular Degeneration (AMD) T E L O M I R P H A R M A . C O M Following promising results with C. After the success achieved with the Exploring Telomir-1’s role in elegans models, Telomir has zebrafish
Slide 10: Pre-Clinical Research: Age Reversal and Increased Longevity
PRE-CLINICAL RESEARCH Age Reversal and Increased Longevity T E L O M I R P H A R M A . C O M White: Hydrogen Blue: Nitrogen Gray: Carbon Orange: Metal Investor Presentation | Nasdaq: TELO 10
Slide 11: Age Reversal and Increased Longevity: Exchange Mechanisms
PRE-CLINICAL RESEARCH Age Reversal and Increased Longevity Exchange mechanisms: Due to the lower affinity of Telomir-1 to Zinc, compared with Iron, Telomir-Zn will exchange the free T E L O M I R P H A R M A . C O M Iron levels in the cells with beneficial Zinc and will chelate the free iron and tak
Slide 12: What are Telomeres?
What are Telomeres? Age Reversal and Increased Longevity Telomeres are the protective end caps of a chromosome made up of DNA sequences and proteins (TTAGGG). Female Male XX XY T E L O M I R P H A R M A . C O M • During cell division, telomeres allow cells to divide without losing genes by protectin
Slide 13: Telomere and Telomere Length
PRE-CLINICAL RESEARCH Age Reversal and Increased Longevity Telomere and Telomer length T E L O M I R P H A R M A . C O M Investor Presentation | Nasdaq: TELO 13
Slide 14: Study Summary and Methodology
PRE-CLINICAL RESEARCH Age Reversal and Increased Longevity Study Summary and Methodology The preclinical study, conducted in collaboration with Nagi Bioscience SA, utilized a sophisticated in vivo microfluidic - based assay to assess the effects of Telomir-1 on the nematode Caenorhabditis elegans, a
Slide 15: Probability of Survival
PRE-CLINICAL RESEARCH Age Reversal and Increased Longevity Effect on Median Lifespan T E L O M I R P H A R M A . C O M Probability of Survival Days Treatment with Telomir-1 significantly enhances life span at the low concentration of 50 µM Investor Presentation | Nasdaq: TELO 15
Slide 16: Age Reversal: Young and Old Population Motility
PRE-CLINICAL RESEARCH Age Reversal and Increased Longevity Young Population Old Population T E L O M I R P H A R M A . C O M (Day 0 – Day 10) (Day 11 – Day 20) Treatment with Telomir-1 significantly enhances several parameters of motility in young and old populations Investor Presentation | Nasdaq:
Slide 17: Study in Progeria - Summary and Methodology
PRE-CLINICAL RESEARCH Age Reversal and Increased Longevity Study in Progeria - Summary and Methodology The preclinical study, conducted in collaboration with Nagi Bioscience SA, used nematodes (C. elegans) having a mutation at the wrn-1 gene. Human equivalent of this gene is implicated in Werner Syn
Slide 18: Reversal of Key Type 2 Diabetes Parameters
PRE-CLINICAL RESEARCH Reversal of Key Type 2 Diabetes Parameters Study Overview and Results In collaboration with Pentagrit, Telomir evaluated two forms of Telomir-1, administered orally at three different doses, in zebrafish models of Type 2 diabetes mellitus induced by a high-calorie diet. The stu
Slide 19: Fasting Blood Glucose Levels – Day 7
PRE-CLINICAL RESEARCH Reversal of Key Type 2 Diabetes Parameters Fasting Blood Glucose Levels – Day 7 T E L O M I R P H A R M A . C O M Telomir-1, in two forms, significantly and dose-dependently normalizes fasting hyperglycemia Investor Presentation | Nasdaq: TELO 19
Slide 20: Oral Glucose Tolerance Test, Area Under the Curves
PRE-CLINICAL RESEARCH Oral Glucose tolerance test (OGTT), Area under the curves Total Area under curve – Day 7 T E L O M I R P H A R M A . C O M Telomir-1, in two forms, significantly and dose-dependently reduces or normalizes glucose AUC levels following OGTT. Investor Presentation | Nasdaq: TELO 2
Slide 21: HOMA-IR
PRE-CLINICAL RESEARCH HOMA –IR-Day 7 T E L O M I R P H A R M A . C O M Telomir-1, in two forms, significantly and dose-dependently significantly reduces or normalizes Homa-IR. Investor Presentation | Nasdaq: TELO 21
Slide 22: On-Going Studies
ON-GOING STUDIES Other Key ongoing Studies Progeria Research Wilson’s Disease Studies on Telomer length In vitro copper toxicity in in human Progeria human cell lines ongoing. cells in vitro Copper induced toxicity in T E L O M I R P H A R M A . C O M mice planned. Type 2 Diabetes Studies Study in d
Slide 23: Anticipated Timeline for Telomir-1
ANTICIPATED TIMELINE FOR TELOMIR-1 T E L O M I R P H A R M A . C O M 2025 2025 2025 2025 Q1 Q2 Q3 Q4 ▪ CMC: Synthesis, Upscaling & ▪ CMC: Stability, Pharmacology: ▪ CMC: GMP, Stability, Drug Formulation Characterization & product development and Consolidation Clinical DP development, ▪ Pharmacology:
Slide 24: Market Opportunity
MARKET OPPORTUNITY Summary of US Epidemiology The eligible patient pool analysisfor Telomir-1 highlights a potential large patient pool looking for potential treatments to their conditions. T E L O M I R P H A R M A . C O M Total Eligible Total Diagnosed Treatment Population Addressable Prevalence R
Slide 25: Market Opportunity for Rare Diseases
MARKET OPPORTUNITY FOR RARE DISEASES Summary of US Epidemiology The eligible patient pool analysis for Telomir-1 highlights a potential large patient pool looking for potential treatments to their conditions. T E L O M I R P H A R M A . C O M Total Eligible Total Diagnosed Population Treatment Rate
Slide 26: Growth Strategy
GROWTH STRATEGY Continue pre-clinical development of Telomir-1 across a range of diseases and progress into clinical development T E L O M I R P H A R M A . C O M Advance Telomir-1 through clinical development and FDA approval Identify additional product candidates and expand current candidates into
Slide 27: Investment Highlights
INVESTMENT HIGHLIGHTS Telomir-1 T E L O M I R P H A R M A . C O M TELOMIR-1 is novel Based on our pre- The Company’s goal is small molecule metal clinical studies to date to explore the potential ion regulator, with a we assemble of Telomir-1 starting broad potential to experimental evidences with o
Slide 28: Thank you.
Thank 100 SE 2nd Street Suite 2000 #1009 you. Miami, FL 33131 TelomirPharma.com
Telomir Pharmaceuticals — Investor Presentation (January 2025) on 6ix